These side effects are also one of the main reasons people stop taking GLP-1s: Around 65% of people without diabetes discontinue within a year Around 47% of people with diabetes discontinue within a year Different GLP-1 medications and dosing schedules are associated with different risks of side effects, and everyones tolerance is different
Occlusion of the Superior Mesenteric Artery in Rats Reversed by Collateral Pathways [PMID: 34073625] Laboratory literature summary: Occlusion of the Superior Mesenteric Artery in Rats Reversed by Collateral Pathways Activation: Gastric Pentadecapeptide BPC 157
The medication, made by Eli Lilly, is approved to treat Type 2 diabetes and also induces weight loss
The label advises monitoring kidney function when starting or increasing doses in people who develop severe gastrointestinal reactions, and it notes that dehydration has been part of reported kidney injury cases
Although data in kidney transplant recipients (KTR) remain limited, the high prevalences of overweight and obesity, post-transplant diabetes mellitus, and cardiovascular disease in this population make GLP-1RAs a promising therapeutic strategy